This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Absolute Antibody
product type :
antibody
product name :
Anti-PD-1 [5C4.B8 (Nivolumab)]
catalog :
Ab00791-23.0
quantity :
200 μg
clonality :
monoclonal
host :
domestic rabbit
conjugate :
nonconjugated
clone name :
5C4.B8 (Nivolumab)
reactivity :
human
application :
immunohistochemistry, neutralization, flow cytometry
product information
Product Name :
Anti-PD-1 [5C4.B8 (Nivolumab)]
Catalog Number :
Ab00791-23.0
Target :
PD-1
Antibody Species :
Rabbit
Isotype :
IgG
LCFormat :
kappa
Target Synonyms :
CD279; programmed death-1; programmed death 1 ; PD1; PD 1; Programmed cell death protein 1; hPD-1; hPD1; hPD 1; BMS-936558; MDX-1106;ONO-4538
Display Amount :
200 μg
PriceGBP :
285
PriceEUR :
315
Product Type :
Primary Antibody
Clonality :
Monoclonal
ApplicationCodesClone :
IHC; FC; SPR; block
Immunogen :
mAb PD1.5 was prepared by immunizing IgH and IgK knock-out transgenic mice possessing a human immunoglobulin (heavy chain) minilocus with recombinant human PD-1-Fc protein consisting of the extracellular domain of PD-1 (amino acids 1–167) and the Fc portion of human IgG1, and Chinese hamster ovary (CHO) cells expressing human PD-1. Nivolumab was generated by grafting the variable regions of PD1.5 onto human kappa and IgG4 constant regions containing an S228P mutation (prevents Fab arm exchange with endogenous IgG4 antibodies).
MarketingCategories :
cancer; melanoma; lung cancer; kidney cancer; oncology; immune system; adaptive immunity; cytokines; biosimilar
Available Custom Conjugation Options :
AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
UniprotAccessionNo :
Q15116
Product Description :
This is a recombinant monoclonal antibody.
company information
Absolute Antibody
Wilton Centre
Redcar
Cleveland
TS10 4RF
Redcar
Cleveland
TS10 4RF
info@absoluteantibody.com
https://absoluteantibody.com/1-617-377-4057
headquarters: United Kingdom
questions and comments